Rheumatoid factor-negative juvenile idiopathic arthritis
diseaseOn this page
Also known as juvenile rheumatoid factor-negative polyarthritispolyarthritis without rheumatoid factorrheumatoid factor-negative JIA
Summary
Rheumatoid factor-negative juvenile idiopathic arthritis (MONDO:0019432) is a disease with 37 cohort genes (31 GWAS associations across 1 studies). The dominant Reactome pathway is MAPK1 (ERK2) activation (3 cohort genes).
At a glance
- Prevalence: 1-9 / 100 000 (Europe)
- Cohort genes: 37
- GWAS associations: 31
- Phenotypes (HPO): 31
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | 8 | Europe | Not yet validated |
Signs & symptoms
Clinical features (HPO)
31 HPO clinical features (Orphanet curated; top 31 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001369 | Arthritis | Frequent (30-79%) |
| HP:0001386 | Joint swelling | Frequent (30-79%) |
| HP:0001387 | Joint stiffness | Frequent (30-79%) |
| HP:0001785 | Ankle swelling | Frequent (30-79%) |
| HP:0002829 | Arthralgia | Frequent (30-79%) |
| HP:0003019 | Abnormality of the wrist | Frequent (30-79%) |
| HP:0003565 | Elevated erythrocyte sedimentation rate | Frequent (30-79%) |
| HP:0005086 | Knee osteoarthritis | Frequent (30-79%) |
| HP:0005186 | Synovial hypertrophy | Frequent (30-79%) |
| HP:0100686 | Enthesitis | Frequent (30-79%) |
| HP:0100769 | Synovitis | Frequent (30-79%) |
| HP:0000554 | Uveitis | Occasional (5-29%) |
| HP:0001155 | Abnormality of the hand | Occasional (5-29%) |
| HP:0001371 | Flexion contracture | Occasional (5-29%) |
| HP:0001384 | Abnormality of the hip joint | Occasional (5-29%) |
| HP:0001530 | Mild postnatal growth retardation | Occasional (5-29%) |
| HP:0001824 | Weight loss | Occasional (5-29%) |
| HP:0001832 | Abnormal metatarsal morphology | Occasional (5-29%) |
| HP:0001903 | Anemia | Occasional (5-29%) |
| HP:0002716 | Lymphadenopathy | Occasional (5-29%) |
| HP:0003043 | Abnormality of the shoulder | Occasional (5-29%) |
| HP:0003319 | Abnormality of the cervical spine | Occasional (5-29%) |
| HP:0003326 | Myalgia | Occasional (5-29%) |
| HP:0003493 | Antinuclear antibody positivity | Occasional (5-29%) |
| HP:0008843 | Hip osteoarthritis | Occasional (5-29%) |
| HP:0010754 | Abnormality of the temporomandibular joint | Occasional (5-29%) |
| HP:0011134 | Low-grade fever | Occasional (5-29%) |
| HP:0011911 | Abnormality of metacarpophalangeal joint | Occasional (5-29%) |
| HP:0040313 | Oligoarthritis | Occasional (5-29%) |
| HP:0001094 | Iridocyclitis | Very rare (<1-4%) |
| HP:0001433 | Hepatosplenomegaly | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | rheumatoid factor-negative juvenile idiopathic arthritis |
| Mondo ID | MONDO:0019432 |
| EFO | EFO:1002020 |
| Orphanet | 85408 |
| UMLS | C3890205 |
| MedGen | 855549 |
| GARD | 0003931 |
| Is cancer (heuristic) | no |
Also known as: juvenile rheumatoid factor-negative polyarthritis · polyarthritis without rheumatoid factor · rheumatoid factor-negative JIA
Data availability: 31 GWAS associations (1 study).
Disease family
An umbrella term covering 2 Mondo subtypes.
Classification path: disease › human disease › disease by body system or component › connective tissue disorder › rheumatic disorder › juvenile idiopathic arthritis › polyarticular juvenile idiopathic arthritis › rheumatoid factor-negative juvenile idiopathic arthritis
Related subtypes (1): rheumatoid factor-positive polyarticular juvenile idiopathic arthritis
Subtypes (2): rheumatoid factor-negative juvenile idiopathic arthritis with anti-nuclear antibodies, rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies
Genetics & variants
GWAS landscape
31 GWAS associations across 1 studies. Top hits map to 25 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs7775055 | 3e-174 | HLA-DQB1 - MTCO3P1 | G | 6.01 |
| rs6679677 | 3e-25 | PHTF1 - RSBN1 | A | 1.59 |
| rs10174238 | 1e-13 | STAT4 | G | 1.29 |
| rs2847293 | 1e-12 | LINC01882 - PTPN2 | A | 1.31 |
| rs10213692 | 3e-11 | ANKRD55 | ? | 1.27 |
| rs1479924 | 6e-11 | IL2 - IL21 | ? | 1.27 |
| rs34536443 | 1e-10 | TYK2 | ? | 1.79 |
| rs7909519 | 8e-10 | IL2RA | ? | 1.39 |
| rs6894249 | 1e-09 | CARINH, IRF1 | ? | 1.32 |
| rs7137828 | 2e-09 | ATXN2 | C | 1.2 |
| rs8129030 | 5e-09 | RUNX1 | ? | 1.28 |
| rs10849448 | 5e-09 | LTBR | A | 1.24 |
| rs2266959 | 6e-09 | UBE2L3 | A | 1.24 |
| rs27293 | 7e-09 | LNPEP | A | 1.31 |
| rs72698115 | 1e-08 | IL6R | C | 1.36 |
| rs3825568 | 1e-08 | ZFP36L1 | ? | 1.3 |
| rs2284033 | 2e-08 | IL2RB | ? | 1.19 |
| rs7127214 | 2e-08 | PRR5L | ? | 1.28 |
| rs7069750 | 3e-08 | FAS | C | 1.18 |
| rs6946509 | 3e-08 | MTCYBP42 - TOMM7 | T | 1.19 |
| rs9532434 | 5e-08 | COG6 | ? | 1.19 |
| rs45539732 | 7e-08 | STAT1 | ? | 1.53 |
| rs73300638 | 1e-07 | JAZF1 | C | 1.28 |
| rs34132030 | 2e-07 | LINC02341 | A | 1.18 |
| rs79893749 | 2e-07 | CCR3 | ? | 1.28 |
| rs11074967 | 2e-07 | RMI2 | ? | 1.18 |
| rs11714843 | 4e-07 | TIMMDC1 | A | 1.22 |
| rs4648881 | 5e-07 | CLIC4 - RUNX3 | G | 1.16 |
| rs149850873 | 5e-07 | PTPN2 | ? | 1.56 |
| rs10194635 | 8e-07 | LINC01104 | T | 1.24 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST005528 | Hinks A | 2013 | 2,816 | 13,056 | Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 1 |
| Tier 2: splice/UTR | 2 |
| Tier 3: regulatory | 1 |
| Tier 4: intronic/intergenic | 27 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 30 |
| low_freq (0.01-0.05) | 1 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 18 |
| intergenic_variant | 8 |
| 5_prime_UTR_variant | 2 |
| non_coding_transcript_exon_variant | 1 |
| missense_variant | 1 |
| regulatory_region_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs7775055 | 6 | 32690139 | T>C | 0.02 | non_coding_transcript_exon_variant | HLA-DQB1 - MTCO3P1 | 3e-174 | Tier 4: intronic/intergenic |
| rs6679677 | 1 | 113761186 | C>A,T | 0.1 | intergenic_variant | PHTF1 - RSBN1 | 3e-25 | Tier 4: intronic/intergenic |
| rs10174238 | 2 | 191108308 | G>A,T | 0.23 | intron_variant | STAT4 | 1e-13 | Tier 4: intronic/intergenic |
| rs2847293 | 18 | 12782449 | A>G,T | 0.17 | intergenic_variant | LINC01882 - PTPN2 | 1e-12 | Tier 4: intronic/intergenic |
| rs10213692 | 5 | 56146422 | T>C,G | 0.25 | intron_variant | ANKRD55 | 3e-11 | Tier 4: intronic/intergenic |
| rs1479924 | 4 | 122466445 | G>A | 0.29 | intergenic_variant | IL2 - IL21 | 6e-11 | Tier 4: intronic/intergenic |
| rs34536443 | 19 | 10352442 | G>C,T | 0.05 | missense_variant | TYK2 | 1e-10 | Tier 1: coding |
| rs7909519 | 10 | 6047878 | T>G | 0.11 | intron_variant | IL2RA | 8e-10 | Tier 4: intronic/intergenic |
| rs6894249 | 5 | 132461855 | A>C,G,T | 0.39 | intron_variant | CARINH, IRF1 | 1e-09 | Tier 4: intronic/intergenic |
| rs7137828 | 12 | 111494996 | C>A,G,T | 0.49 | intron_variant | ATXN2 | 2e-09 | Tier 4: intronic/intergenic |
| rs8129030 | 21 | 35340290 | T>A,G | 0.37 | intergenic_variant | RUNX1 | 5e-09 | Tier 4: intronic/intergenic |
| rs10849448 | 12 | 6384185 | A>G | 0.24 | 5_prime_UTR_variant | LTBR | 5e-09 | Tier 2: splice/UTR |
| rs2266959 | 22 | 21568615 | G>A,T | 0.19 | intron_variant | UBE2L3 | 6e-09 | Tier 4: intronic/intergenic |
| rs27293 | 5 | 97021474 | A>G,T | 0.44 | intron_variant | LNPEP | 7e-09 | Tier 4: intronic/intergenic |
| rs72698115 | 1 | 154406893 | A>C | 0.1 | intron_variant | IL6R | 1e-08 | Tier 4: intronic/intergenic |
| rs3825568 | 14 | 68793871 | C>G,T | 0.44 | 5_prime_UTR_variant | ZFP36L1 | 1e-08 | Tier 2: splice/UTR |
| rs2284033 | 22 | 37137994 | G>A,C | 0.44 | intron_variant | IL2RB | 2e-08 | Tier 4: intronic/intergenic |
| rs7127214 | 11 | 36322143 | C>G,T | 0.35 | intron_variant | PRR5L | 2e-08 | Tier 4: intronic/intergenic |
| rs7069750 | 10 | 89002619 | G>C,T | 0.44 | intron_variant | FAS | 3e-08 | Tier 4: intronic/intergenic |
| rs6946509 | 7 | 22769871 | T>A,C | 0.45 | intergenic_variant | MTCYBP42 - TOMM7 | 3e-08 | Tier 4: intronic/intergenic |
| rs9532434 | 13 | 39781776 | T>A,C | 0.36 | intergenic_variant | COG6 | 5e-08 | Tier 4: intronic/intergenic |
| rs45539732 | 2 | 191009521 | T>C | 0.05 | intron_variant | STAT1 | 7e-08 | Tier 4: intronic/intergenic |
| rs73300638 | 7 | 28147725 | A>C,G | 0.11 | intron_variant | JAZF1 | 1e-07 | Tier 4: intronic/intergenic |
| rs34132030 | 13 | 42481900 | C>T | 0.32 | intergenic_variant | LINC02341 | 2e-07 | Tier 4: intronic/intergenic |
| rs79893749 | 3 | 46212159 | C>T | 0.15 | intron_variant | CCR3 | 2e-07 | Tier 4: intronic/intergenic |
| rs11074967 | 16 | 11377557 | C>G,T | 0.42 | intron_variant | RMI2 | 2e-07 | Tier 4: intronic/intergenic |
| rs11714843 | 3 | 119502217 | T>A | 0.18 | intron_variant | TIMMDC1 | 4e-07 | Tier 4: intronic/intergenic |
| rs4648881 | 1 | 24870664 | G>A | 0.49 | regulatory_region_variant | CLIC4 - RUNX3 | 5e-07 | Tier 3: regulatory |
| rs149850873 | 18 | 12885121 | G>A,T | 0.05 | intergenic_variant | PTPN2 | 5e-07 | Tier 4: intronic/intergenic |
| rs10194635 | 2 | 100217755 | T>A,G | 0.39 | intron_variant | LINC01104 | 8e-07 | Tier 4: intronic/intergenic |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 49 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 8
Dual-evidence genes (GWAS + Mendelian — highest-confidence targets)
| Gene | HGNC | Evidence routes |
|---|---|---|
| STAT4 | STAT4 | GWAS, Orphanet |
| ANKRD55 | ANKRD55 | GWAS, Orphanet |
| HLA-DQB1 | HLA-DQB1 | GWAS, Orphanet |
| IL2RA | IL2RA | GWAS, Orphanet |
| IL2RB | IL2RB | GWAS, Orphanet |
| IL6 | IL6 | GWAS, Orphanet |
| PTPN2 | PTPN2 | GWAS, Orphanet |
| PTPN22 | PTPN22 | GWAS, Orphanet |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| RUNX1 | Orphanet:102724 | Acute myeloid leukemia with t(8;21)(q22;q22) translocation |
| RUNX1 | Orphanet:521 | Chronic myeloid leukemia |
| RUNX1 | Orphanet:71290 | Familial platelet disorder with associated myeloid malignancy |
| RUNX1 | Orphanet:98850 | Aggressive systemic mastocytosis |
| ATXN2 | Orphanet:803 | Amyotrophic lateral sclerosis |
| ATXN2 | Orphanet:98756 | Spinocerebellar ataxia type 2 |
| STAT4 | Orphanet:117 | Behçet disease |
| STAT4 | Orphanet:536 | Systemic lupus erythematosus |
| STAT4 | Orphanet:85408 | Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis |
| STAT4 | Orphanet:85410 | Oligoarticular juvenile idiopathic arthritis |
| STAT4 | Orphanet:93552 | Pediatric systemic lupus erythematosus |
| TYK2 | Orphanet:300865 | Primary cutaneous anaplastic large cell lymphoma |
| TYK2 | Orphanet:331226 | Susceptibility to infection due to TYK2 deficiency |
| TYK2 | Orphanet:98842 | Lymphomatoid papulosis |
| UBE2L3 | Orphanet:536 | Systemic lupus erythematosus |
| TIMMDC1 | Orphanet:2609 | Isolated complex I deficiency |
| CCR1 | Orphanet:117 | Behçet disease |
| COG6 | Orphanet:363523 | Hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndrome |
| COG6 | Orphanet:464443 | COG6-CGD |
| ANKRD55 | Orphanet:85408 | Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis |
| ANKRD55 | Orphanet:85410 | Oligoarticular juvenile idiopathic arthritis |
| RMI2 | Orphanet:508512 | Intrauterine growth restriction-congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome |
| JAZF1 | Orphanet:213711 | Endometrial stromal sarcoma |
| JAZF1 | Orphanet:536 | Systemic lupus erythematosus |
| SH2B3 | Orphanet:3318 | Essential thrombocythemia |
| SH2B3 | Orphanet:391366 | Growth retardation-mild developmental delay-chronic hepatitis syndrome |
| HLA-DQB1 | Orphanet:2073 | Narcolepsy type 1 |
| HLA-DQB1 | Orphanet:477738 | Pediatric multiple sclerosis |
| HLA-DQB1 | Orphanet:703 | Bullous pemphigoid |
| HLA-DQB1 | Orphanet:83465 | Narcolepsy type 2 |
| HLA-DQB1 | Orphanet:930 | Idiopathic achalasia |
| IL21 | Orphanet:477661 | IL21-related infantile inflammatory bowel disease |
| IL2RA | Orphanet:169100 | Immunodeficiency due to CD25 deficiency |
| IL2RA | Orphanet:85408 | Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis |
| IL2RA | Orphanet:85410 | Oligoarticular juvenile idiopathic arthritis |
| IL2RB | Orphanet:85408 | Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis |
| IL2RB | Orphanet:85410 | Oligoarticular juvenile idiopathic arthritis |
| IL6 | Orphanet:85414 | Systemic-onset juvenile idiopathic arthritis |
| IL6R | Orphanet:656326 | Autosomal recessive combined immunodeficiency due to IL6R deficiency |
| IRF1 | Orphanet:699615 | Severe mendelian susceptibility to mycobacterial diseases due to complete IRF1 deficiency |
| AFF3 | Orphanet:632603 | Mesomelic dysplasia-digital anomalies-intellectual disability syndrome |
| PTPN2 | Orphanet:85408 | Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis |
| PTPN2 | Orphanet:85410 | Oligoarticular juvenile idiopathic arthritis |
| PTPN22 | Orphanet:3437 | Vogt-Koyanagi-Harada disease |
| PTPN22 | Orphanet:397 | Giant cell arteritis |
| PTPN22 | Orphanet:536 | Systemic lupus erythematosus |
| PTPN22 | Orphanet:85408 | Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis |
| PTPN22 | Orphanet:85410 | Oligoarticular juvenile idiopathic arthritis |
| PTPN22 | Orphanet:900 | Granulomatosis with polyangiitis |
Cohort genes → proteins
37 cohort genes, 36 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| gwas_only | 37 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| RUNX1 | HGNC:10471 | ENSG00000159216 | Q01196 | Runt-related transcription factor 1 | gwas |
| RUNX3 | HGNC:10473 | ENSG00000020633 | Q13761 | Runt-related transcription factor 3 | gwas |
| ATXN2 | HGNC:10555 | ENSG00000204842 | Q99700 | Ataxin-2 | gwas |
| ZFP36L1 | HGNC:1107 | ENSG00000185650 | Q07352 | mRNA decay activator protein ZFP36L1 | gwas |
| STAT4 | HGNC:11365 | ENSG00000138378 | Q14765 | Signal transducer and activator of transcription 4 | gwas |
| TYK2 | HGNC:12440 | ENSG00000105397 | P29597 | Non-receptor tyrosine-protein kinase TYK2 | gwas |
| UBE2L3 | HGNC:12488 | ENSG00000185651 | P68036 | Ubiquitin-conjugating enzyme E2 L3 | gwas |
| TIMMDC1 | HGNC:1321 | ENSG00000113845 | Q9NPL8 | Complex I assembly factor TIMMDC1, mitochondrial | gwas |
| ATP8B2 | HGNC:13534 | ENSG00000143515 | P98198 | Phospholipid-transporting ATPase ID | gwas |
| CCR1 | HGNC:1602 | ENSG00000163823 | P32246 | C-C chemokine receptor type 1 | gwas |
| CCR3 | HGNC:1604 | ENSG00000183625 | P51677 | C-C chemokine receptor type 3 | gwas |
| CD80 | HGNC:1700 | ENSG00000121594 | P33681 | T-lymphocyte activation antigen CD80 | gwas |
| COG6 | HGNC:18621 | ENSG00000133103 | Q9Y2V7 | Conserved oligomeric Golgi complex subunit 6 | gwas |
| LONRF2 | HGNC:24788 | ENSG00000170500 | Q1L5Z9 | LON peptidase N-terminal domain and RING finger protein 2 | gwas |
| ANKRD55 | HGNC:25681 | ENSG00000164512 | Q3KP44 | Ankyrin repeat domain-containing protein 55 | gwas |
| PRR5L | HGNC:25878 | ENSG00000135362 | Q6MZQ0 | Proline-rich protein 5-like | gwas |
| RMI2 | HGNC:28349 | ENSG00000175643 | Q96E14 | RecQ-mediated genome instability protein 2 | gwas |
| JAZF1 | HGNC:28917 | ENSG00000153814 | Q86VZ6 | Juxtaposed with another zinc finger protein 1 | gwas |
| ERAP2 | HGNC:29499 | ENSG00000164308 | Q6P179 | Endoplasmic reticulum aminopeptidase 2 | gwas |
| SH2B3 | HGNC:29605 | ENSG00000111252 | Q9UQQ2 | SH2B adapter protein 3 | gwas |
| CARINH | HGNC:33838 | ENSG00000197536 | colitis associated IRF1 antisense regulator of intestinal homeostasis | gwas | |
| FASN | HGNC:3594 | ENSG00000169710 | P49327 | Fatty acid synthase | gwas |
| HLA-DQA2 | HGNC:4943 | ENSG00000237541 | P01906 | HLA class II histocompatibility antigen, DQ alpha 2 chain | gwas |
| HLA-DQB1 | HGNC:4944 | ENSG00000179344 | P01920 | HLA class II histocompatibility antigen, DQ beta 1 chain | gwas |
| IL2 | HGNC:6001 | ENSG00000109471 | P60568 | Interleukin-2 | gwas |
| IL21 | HGNC:6005 | ENSG00000138684 | Q9HBE4 | Interleukin-21 | gwas |
| IL2RA | HGNC:6008 | ENSG00000134460 | P01589 | Interleukin-2 receptor subunit alpha | gwas |
| IL2RB | HGNC:6009 | ENSG00000100385 | P14784 | Interleukin-2 receptor subunit beta | gwas |
| IL6 | HGNC:6018 | ENSG00000136244 | P05231 | Interleukin-6 | gwas |
| IL6R | HGNC:6019 | ENSG00000160712 | P08887 | Interleukin-6 receptor subunit alpha | gwas |
| IRF1 | HGNC:6116 | ENSG00000125347 | P10914 | Interferon regulatory factor 1 | gwas |
| AFF3 | HGNC:6473 | ENSG00000144218 | P51826 | AF4/FMR2 family member 3 | gwas |
| LNPEP | HGNC:6656 | ENSG00000113441 | Q9UIQ6 | Leucyl-cystinyl aminopeptidase | gwas |
| LTBR | HGNC:6718 | ENSG00000111321 | P36941 | Tumor necrosis factor receptor superfamily member 3 | gwas |
| PRM1 | HGNC:9447 | ENSG00000175646 | P04553 | Sperm protamine P1 | gwas |
| PTPN2 | HGNC:9650 | ENSG00000175354 | P17706 | Tyrosine-protein phosphatase non-receptor type 2 | gwas |
| PTPN22 | HGNC:9652 | ENSG00000134242 | Q9Y2R2 | Tyrosine-protein phosphatase non-receptor type 22 | gwas |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| RUNX1 | Runt-related transcription factor 1 | Forms the heterodimeric complex core-binding factor (CBF) with CBFB. |
| RUNX3 | Runt-related transcription factor 3 | Forms the heterodimeric complex core-binding factor (CBF) with CBFB. |
| ATXN2 | Ataxin-2 | Involved in EGFR trafficking, acting as negative regulator of endocytic EGFR internalization at the plasma membrane. |
| ZFP36L1 | mRNA decay activator protein ZFP36L1 | Zinc-finger RNA-binding protein that destabilizes several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthes… |
| STAT4 | Signal transducer and activator of transcription 4 | Transcriptional regulator mainly expressed in hematopoietic cells that plays a critical role in cellular growth, differentiation and immune response. |
| TYK2 | Non-receptor tyrosine-protein kinase TYK2 | Tyrosine kinase of the non-receptor type involved in numerous cytokines and interferons signaling, which regulates cell growth, development, cell migration, innate and adaptive immunity. |
| UBE2L3 | Ubiquitin-conjugating enzyme E2 L3 | Ubiquitin-conjugating enzyme E2 that specifically acts with HECT-type and RBR family E3 ubiquitin-protein ligases. |
| TIMMDC1 | Complex I assembly factor TIMMDC1, mitochondrial | Chaperone protein involved in the assembly of the mitochondrial NADH:ubiquinone oxidoreductase complex (complex I). |
| ATP8B2 | Phospholipid-transporting ATPase ID | Catalytic component of P4-ATPase flippase complex, which catalyzes the hydrolysis of ATP coupled to the transport of phosphatidylcholine (PC) from the outer to the inner leaflet of the plasma membrane. |
| CCR1 | C-C chemokine receptor type 1 | Chemokine receptor that plays a crucial role in regulating immune cell migration, inflammation, and immune responses. |
| CCR3 | C-C chemokine receptor type 3 | G protein-coupled receptor (GPCR) that plays a key role in the immune system by regulating the migration and activation of white blood cells in response to chemokines. |
| CD80 | T-lymphocyte activation antigen CD80 | Costimulatory molecule that belongs to the immunoglobulin superfamily that plays an important role in T-lymphocyte activation. |
| COG6 | Conserved oligomeric Golgi complex subunit 6 | Required for normal Golgi function. |
| PRR5L | Proline-rich protein 5-like | Associates with the mTORC2 complex that regulates cellular processes including survival and organization of the cytoskeleton. |
| RMI2 | RecQ-mediated genome instability protein 2 | Essential component of the RMI complex, a complex that plays an important role in the processing of homologous recombination intermediates. |
| JAZF1 | Juxtaposed with another zinc finger protein 1 | Acts as a transcriptional corepressor of orphan nuclear receptor NR2C2. |
| ERAP2 | Endoplasmic reticulum aminopeptidase 2 | Aminopeptidase that plays a central role in peptide trimming, a step required for the generation of most HLA class I-binding peptides. |
| SH2B3 | SH2B adapter protein 3 | Links T-cell receptor activation signal to phospholipase C-gamma-1, GRB2 and phosphatidylinositol 3-kinase. |
| FASN | Fatty acid synthase | Fatty acid synthetase is a multifunctional enzyme that catalyzes the de novo biosynthesis of long-chain saturated fatty acids starting from acetyl-CoA and malonyl-CoA in the presence of NADPH. |
| HLA-DQA2 | HLA class II histocompatibility antigen, DQ alpha 2 chain | Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. |
| HLA-DQB1 | HLA class II histocompatibility antigen, DQ beta 1 chain | Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. |
| IL2 | Interleukin-2 | Cytokine produced by activated CD4-positive helper T-cells and to a lesser extend activated CD8-positive T-cells and natural killer (NK) cells that plays pivotal roles in the immune response and tolerance. |
| IL21 | Interleukin-21 | Cytokine with immunoregulatory activity. |
| IL2RA | Interleukin-2 receptor subunit alpha | Receptor for interleukin-2. |
| IL2RB | Interleukin-2 receptor subunit beta | Receptor for interleukin-2. |
| IL6 | Interleukin-6 | Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. |
| IL6R | Interleukin-6 receptor subunit alpha | Part of the receptor for interleukin 6. |
| IRF1 | Interferon regulatory factor 1 | Transcriptional regulator which displays a remarkable functional diversity in the regulation of cellular responses. |
| AFF3 | AF4/FMR2 family member 3 | Putative transcription activator that may function in lymphoid development and oncogenesis. |
| LNPEP | Leucyl-cystinyl aminopeptidase | Release of an N-terminal amino acid, cleaves before cysteine, leucine as well as other amino acids. |
| LTBR | Tumor necrosis factor receptor superfamily member 3 | Receptor for the heterotrimeric lymphotoxin containing LTA and LTB, and for TNFS14/LIGHT. |
| PRM1 | Sperm protamine P1 | Protamines substitute for histones in the chromatin of sperm during the haploid phase of spermatogenesis. |
| PTPN2 | Tyrosine-protein phosphatase non-receptor type 2 | Non-receptor type tyrosine-specific phosphatase that dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR. |
| PTPN22 | Tyrosine-protein phosphatase non-receptor type 22 | Acts as a negative regulator of T-cell receptor (TCR) signaling by direct dephosphorylation of the Src family kinases LCK and FYN, ITAMs of the TCRz/CD3 complex, as well as ZAP70, VAV, VCP and other key signaling molecules. |
Protein-family classification
Druggable: 15 · Difficult: 9 · Unknown: 13 · Druggable fraction: 0.41
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Antibody/Immunoglobulin | 5 | 3.9× | 0.082 |
| Phosphatase | 2 | 4.5× | 0.359 |
| Complement | 1 | 7.2× | 0.384 |
| Transcription factor | 7 | 1.6× | 0.384 |
| Protease | 2 | 2.0× | 0.536 |
| GPCR | 2 | 1.3× | 0.769 |
| Scaffold/PPI | 2 | 0.9× | 0.913 |
| Kinase | 1 | 0.8× | 0.918 |
| Enzyme (other) | 2 | 0.7× | 0.918 |
| Other/Unknown | 13 | 0.6× | 0.997 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| RUNX1 | Transcription factor | no | AML1_Runt, p53-like_TF_DNA-bd_sf, p53/RUNT-type_TF_DNA-bd_sf | |
| RUNX3 | Transcription factor | no | AML1_Runt, p53-like_TF_DNA-bd_sf, p53/RUNT-type_TF_DNA-bd_sf | |
| ATXN2 | Other/Unknown | no | LsmAD_domain, PAM2_motif, LSM_dom_sf | |
| ZFP36L1 | Transcription factor | no | Znf_CCCH, Tis11B_N, Znf_CCCH_sf | |
| STAT4 | Transcription factor | no | SH2, STAT, p53-like_TF_DNA-bd_sf | |
| TYK2 | Kinase | yes | 2.7.10.2 | FERM_domain, Prot_kinase_dom, SH2 |
| UBE2L3 | Enzyme (other) | yes | 2.3.2.23 | UBC, UBQ-conjugating_enzyme/RWD, UBQ-conjugating_AS |
| TIMMDC1 | Other/Unknown | no | TIMMDC1 | |
| ATP8B2 | Transcription factor | no | 7.6.2.1 | P_typ_ATPase, P-type_ATPase_IV, ATPase_P-typ_transduc_dom_A_sf |
| CCR1 | GPCR | yes | GPCR_Rhodpsn, Chemokine_rcpt, Chemokine_CCR1 | |
| CCR3 | GPCR | yes | GPCR_Rhodpsn, Chemokine_rcpt, Chemokine_CCR3 | |
| CD80 | Antibody/Immunoglobulin | yes | Ig_sub, Ig-like_dom, Ig_V-set | |
| COG6 | Other/Unknown | no | COG6, COG6_N, COG6_C | |
| LONRF2 | Transcription factor | no | Znf_RING, Lon_prtase_N, TPR-like_helical_dom_sf | |
| ANKRD55 | Scaffold/PPI | no | Ankyrin_rpt, Ankyrin_rpt-contain_sf | |
| PRR5L | Other/Unknown | no | Bit61/PRR5 | |
| RMI2 | Other/Unknown | no | NA-bd_OB-fold, RMI2 | |
| JAZF1 | Transcription factor | no | Znf_C2H2_type, Znf_C2H2_sf, ZnF-Chromatin_assoc | |
| ERAP2 | Protease | yes | 3.4.11.1 | Peptidase_M1, Peptidase_M1_dom, ERAP1-like_C_dom |
| SH2B3 | Scaffold/PPI | no | SH2, PH_domain, PH-like_dom_sf | |
| CARINH | Other/Unknown | no | ||
| FASN | Enzyme (other) | yes | 2.3.1.39 | Thioesterase, Ac_transferase_dom_sf, Ppantetheine_attach_site |
| HLA-DQA2 | Antibody/Immunoglobulin | yes | MHC_II_a_N, Ig/MHC_CS, Ig_C1-set | |
| HLA-DQB1 | Antibody/Immunoglobulin | yes | MHC_II_b_N, Ig/MHC_CS, Ig_C1-set | |
| IL2 | Other/Unknown | no | IL-2, 4_helix_cytokine-like_core, IL-2_CS | |
| IL21 | Other/Unknown | no | IL-15/IL-21_fam, 4_helix_cytokine-like_core | |
| IL2RA | Complement | yes | Sushi_SCR_CCP_dom, IL-2_rcpt_alpha, Sushi/SCR/CCP_sf | |
| IL2RB | Antibody/Immunoglobulin | yes | Hempt_rcpt_S_F1_CS, FN3_dom, Ig-like_fold | |
| IL6 | Other/Unknown | no | IL-6-like, 4_helix_cytokine-like_core, IL6/GCSF/MGF_CS | |
| IL6R | Antibody/Immunoglobulin | yes | Hematopoietin_rcpt_L_F3_CS, Ig_sub2, Ig_sub | |
| IRF1 | Other/Unknown | no | Interferon_reg_fact_DNA-bd_dom, IRF1/IRF2, Interferon_reg_fac_CS | |
| AFF3 | Other/Unknown | no | AF4/FMR2, AF4_int, AF4/FMR2_CHD | |
| LNPEP | Protease | yes | 3.4.11.3 | Peptidase_M1, Peptidase_M1_dom, ERAP1-like_C_dom |
| LTBR | Other/Unknown | no | TNFR/NGFR_Cys_rich_reg, TNFR_3_LTBR, TNFRSF3_N | |
| PRM1 | Other/Unknown | no | Protamine_P1 | |
| PTPN2 | Phosphatase | yes | 3.1.3.48 | PTP_cat, Tyr_Pase_dom, Tyr_Pase_cat |
| PTPN22 | Phosphatase | yes | 3.1.3.48 | PTP_cat, Tyr_Pase_dom, Tyr_Pase_cat |
Expression context
Cohort genes with no expression data: 0.
35 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 37 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| granulocyte | 10 |
| monocyte | 6 |
| male germ line stem cell (sensu Vertebrata) in testis | 5 |
| buccal mucosa cell | 4 |
| leukocyte | 4 |
| lymph node | 3 |
| sperm | 3 |
| secondary oocyte | 3 |
| mucosa of paranasal sinus | 2 |
| olfactory bulb | 2 |
| mucosa of stomach | 2 |
| middle temporal gyrus | 2 |
| right hemisphere of cerebellum | 2 |
| mucosa of transverse colon | 2 |
| oocyte | 2 |
| mononuclear cell | 2 |
| blood | 2 |
| pancreatic ductal cell | 2 |
| tibia | 2 |
| Brodmann (1909) area 23 | 2 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| RUNX1 | 253 | ubiquitous | marker | olfactory segment of nasal mucosa, epithelium of bronchus, mucosa of paranasal sinus |
| RUNX3 | 220 | broad | marker | granulocyte, buccal mucosa cell, lymph node |
| ATXN2 | 286 | ubiquitous | marker | buccal mucosa cell, colonic epithelium, olfactory bulb |
| ZFP36L1 | 289 | ubiquitous | marker | mucosa of paranasal sinus, endocervix, mucosa of stomach |
| STAT4 | 201 | broad | marker | granulocyte, sperm, middle temporal gyrus |
| TYK2 | 288 | ubiquitous | marker | granulocyte, right hemisphere of cerebellum, adenohypophysis |
| UBE2L3 | 287 | ubiquitous | marker | oocyte, secondary oocyte, mucosa of transverse colon |
| TIMMDC1 | 259 | ubiquitous | marker | left ventricle myocardium, cardiac muscle of right atrium, myocardium |
| ATP8B2 | 250 | ubiquitous | marker | mucosa of stomach, right coronary artery, stromal cell of endometrium |
| CCR1 | 244 | broad | marker | monocyte, mononuclear cell, leukocyte |
| CCR3 | 100 | tissue_specific | yes | secondary oocyte, blood, oocyte |
| CD80 | 143 | broad | marker | male germ line stem cell (sensu Vertebrata) in testis, lower lobe of lung, pancreatic ductal cell |
| COG6 | 254 | ubiquitous | marker | secondary oocyte, tibia, calcaneal tendon |
| LONRF2 | 235 | broad | marker | corpus epididymis, Brodmann (1909) area 23, middle temporal gyrus |
| ANKRD55 | 169 | broad | marker | male germ line stem cell (sensu Vertebrata) in testis, sperm, primordial germ cell in gonad |
| PRR5L | 203 | ubiquitous | marker | mucosa of transverse colon, granulocyte, rectum |
| RMI2 | 187 | ubiquitous | marker | ventricular zone, ileal mucosa, ganglionic eminence |
| JAZF1 | 251 | ubiquitous | marker | trabecular bone tissue, cauda epididymis, right adrenal gland cortex |
| ERAP2 | 244 | ubiquitous | marker | buccal mucosa cell, granulocyte, lymph node |
| SH2B3 | 260 | ubiquitous | marker | monocyte, mononuclear cell, leukocyte |
| CARINH | 239 | ubiquitous | marker | granulocyte, bone marrow cell, pancreatic ductal cell |
| FASN | 273 | ubiquitous | marker | right hemisphere of cerebellum, endometrium epithelium, skin of abdomen |
| HLA-DQA2 | 127 | broad | marker | granulocyte, vermiform appendix, male germ line stem cell (sensu Vertebrata) in testis |
| HLA-DQB1 | 268 | broad | marker | right lung, spleen, upper lobe of left lung |
| IL2 | 92 | yes | primordial germ cell in gonad, male germ line stem cell (sensu Vertebrata) in testis, buccal mucosa cell | |
| IL21 | 26 | marker | male germ line stem cell (sensu Vertebrata) in testis, olfactory bulb, type B pancreatic cell | |
| IL2RA | 153 | broad | marker | lymph node, vermiform appendix, caecum |
| IL2RB | 208 | broad | marker | granulocyte, decidua, ileal mucosa |
| IL6 | 200 | ubiquitous | marker | cartilage tissue, vena cava, gall bladder |
| IL6R | 271 | ubiquitous | marker | blood, monocyte, leukocyte |
Protein interactions among cohort
Intra-cohort edges: 20.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| IL6 | 9,239 |
| FASN | 6,551 |
| RUNX1 | 4,994 |
| IRF1 | 4,076 |
| TYK2 | 3,932 |
| CD80 | 3,664 |
| ATXN2 | 3,360 |
| RUNX3 | 3,293 |
| CCR1 | 2,912 |
| IL6R | 2,805 |
Intra-cohort edges
| A | B | Sources |
|---|---|---|
| AFF3 | ANKRD55 | string_interaction |
| AFF3 | LONRF2 | string_interaction |
| AFF3 | PTPN22 | string_interaction |
| ANKRD55 | PTPN22 | string_interaction |
| ATXN2 | SH2B3 | string_interaction |
| CCR1 | CCR3 | string_interaction |
| IL2 | IL2RA | intact |
| IL2 | IL2RB | intact |
| IL2RA | IL2RB | string_interaction |
| IL2RA | PTPN2 | string_interaction |
| IL6 | IL6R | biogrid_interaction, intact, string_interaction |
| IL6 | STAT4 | string_interaction |
| IL6 | TYK2 | string_interaction |
| IL6R | TYK2 | string_interaction |
| LONRF2 | PRR5L | string_interaction |
| PTPN2 | SH2B3 | string_interaction |
| PTPN2 | STAT4 | string_interaction |
| PTPN22 | STAT4 | string_interaction |
| RUNX1 | RUNX3 | string_interaction |
| STAT4 | TYK2 | string_interaction |
Structural data
PDB: 23 · AlphaFold-only: 13 · No structure: 1
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| TYK2 | P29597 | 52 |
| IL2 | P60568 | 37 |
| FASN | P49327 | 34 |
| UBE2L3 | P68036 | 21 |
| IL6 | P05231 | 17 |
| ERAP2 | Q6P179 | 14 |
| PTPN2 | P17706 | 14 |
| PTPN22 | Q9Y2R2 | 14 |
| LNPEP | Q9UIQ6 | 11 |
| HLA-DQB1 | P01920 | 10 |
| IL2RA | P01589 | 10 |
| IL6R | P08887 | 10 |
| IL2RB | P14784 | 8 |
| CD80 | P33681 | 6 |
| RMI2 | Q96E14 | 6 |
| RUNX1 | Q01196 | 5 |
| CCR1 | P32246 | 3 |
| IL21 | Q9HBE4 | 3 |
| ZFP36L1 | Q07352 | 2 |
| LTBR | P36941 | 2 |
| RUNX3 | Q13761 | 1 |
| ATXN2 | Q99700 | 1 |
| CCR3 | P51677 | 1 |
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| HLA-DQA2 | P01906 | 89.29 |
| STAT4 | Q14765 | 86.87 |
| COG6 | Q9Y2V7 | 86.62 |
| ATP8B2 | P98198 | 82.24 |
| LONRF2 | Q1L5Z9 | 78.97 |
| TIMMDC1 | Q9NPL8 | 72.08 |
| JAZF1 | Q86VZ6 | 70.25 |
| PRR5L | Q6MZQ0 | 68.40 |
| IRF1 | P10914 | 66.65 |
| SH2B3 | Q9UQQ2 | 63.45 |
| ANKRD55 | Q3KP44 | 63.43 |
| PRM1 | P04553 | 54.01 |
| AFF3 | P51826 | 52.20 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 196. Enrichment computed across 37 evidence-associated genes (30 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 30 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| MAPK1 (ERK2) activation | 3 | 114.2× | 1e-04 | TYK2, IL6, IL6R |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | 3 | 114.2× | 1e-04 | RUNX1, IL2, IL2RA |
| MAPK3 (ERK1) activation | 3 | 103.8× | 1e-04 | TYK2, IL6, IL6R |
| Interleukin-6 signaling | 3 | 95.2× | 1e-04 | TYK2, IL6, IL6R |
| Interleukin-2 signaling | 3 | 95.2× | 1e-04 | IL2, IL2RA, IL2RB |
| Differentiation of naive CD4+ T cells to T helper 1 cells (Th1 cells) | 3 | 87.8× | 2e-04 | RUNX1, RUNX3, STAT4 |
| Interleukin-10 signaling | 4 | 31.1× | 2e-04 | TYK2, CCR1, CD80, IL6 |
| RUNX3 regulates RUNX1-mediated transcription | 2 | 253.8× | 5e-04 | RUNX1, RUNX3 |
| Interleukin receptor SHC signaling | 3 | 40.8× | 0.001 | IL2, IL2RA, IL2RB |
| Interleukin-23 signaling | 2 | 84.6× | 0.005 | STAT4, TYK2 |
| RUNX3 regulates p14-ARF | 2 | 76.1× | 0.005 | RUNX1, RUNX3 |
| Interleukin-21 signaling | 2 | 76.1× | 0.005 | STAT4, IL21 |
| Interleukin-35 Signalling | 2 | 63.4× | 0.007 | STAT4, TYK2 |
| Cytokine Signaling in Immune system | 5 | 6.8× | 0.010 | STAT4, CCR1, CD80, SH2B3, IRF1 |
| Activation of STAT3 by cadherin engagement | 3 | 16.3× | 0.010 | TYK2, IL6, IL6R |
| Translocation of ZAP-70 to Immunological synapse | 2 | 42.3× | 0.012 | HLA-DQA2, PTPN22 |
| Phosphorylation of CD3 and TCR zeta chains | 2 | 36.2× | 0.016 | HLA-DQA2, PTPN22 |
| Interferon gamma signaling | 3 | 12.6× | 0.019 | HLA-DQA2, HLA-DQB1, IRF1 |
| Interleukin-20 family signaling | 2 | 28.2× | 0.023 | STAT4, TYK2 |
| Interleukin-12 signaling | 2 | 27.2× | 0.024 | STAT4, TYK2 |
| Interleukin-4 and Interleukin-13 signaling | 3 | 10.3× | 0.028 | TYK2, IL6, IL6R |
| Transcriptional regulation by RUNX3 | 2 | 18.1× | 0.048 | RUNX1, RUNX3 |
| RUNX1 regulates expression of components of tight junctions | 1 | 76.1× | 0.088 | RUNX1 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | 1 | 76.1× | 0.088 | RUNX1 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | 1 | 76.1× | 0.088 | RUNX1 |
| RUNX3 regulates BCL2L11 (BIM) transcription | 1 | 76.1× | 0.088 | RUNX3 |
| Chemokine receptors bind chemokines | 2 | 12.5× | 0.088 | CCR1, CCR3 |
| Signaling by Interleukins | 3 | 6.4× | 0.088 | STAT4, CCR1, CD80 |
| RAF/MAP kinase cascade | 3 | 6.1× | 0.088 | IL2, IL2RA, IL2RB |
| RUNX1 regulates estrogen receptor mediated transcription | 1 | 63.4× | 0.093 | RUNX1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 35 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| immune response | 9 | 12.1× | 1e-05 | TYK2, CCR1, CCR3, CD80, HLA-DQA2, HLA-DQB1, IL2, IL2RA (+1 more) |
| positive regulation of interleukin-17 production | 4 | 68.8× | 4e-05 | TYK2, IL2, IL21, IL6 |
| cytokine-mediated signaling pathway | 6 | 22.4× | 4e-05 | STAT4, TYK2, CCR1, IL2RB, IL6, IL6R |
| interleukin-2-mediated signaling pathway | 3 | 180.6× | 5e-05 | IL2, IL2RA, IL2RB |
| regulation of CD4-positive, alpha-beta T cell proliferation | 2 | 481.5× | 4e-04 | IL2, IL2RA |
| hepatic immune response | 2 | 321.0× | 7e-04 | IL6, IL6R |
| regulation of T cell homeostatic proliferation | 2 | 321.0× | 7e-04 | IL2, IL2RA |
| positive regulation of T cell proliferation | 4 | 29.6× | 7e-04 | TYK2, CD80, IL21, IL6 |
| positive regulation of type II interferon production | 4 | 25.7× | 8e-04 | TYK2, IL2, IL21, PTPN22 |
| negative regulation of CD4-positive, alpha-beta T cell differentiation | 2 | 240.7× | 0.001 | RUNX1, RUNX3 |
| monocyte chemotaxis | 3 | 49.8× | 0.001 | CCR1, IL6, IL6R |
| cell surface receptor signaling pathway via STAT | 3 | 48.1× | 0.001 | IL2, IL6, IL6R |
| positive regulation of CD8-positive, alpha-beta T cell differentiation | 2 | 192.6× | 0.001 | RUNX1, RUNX3 |
| positive regulation of immunoglobulin production | 3 | 41.3× | 0.002 | IL2, IL21, IL6 |
| positive regulation of tissue remodeling | 2 | 160.5× | 0.002 | IL2, IL21 |
| vascular endothelial growth factor production | 2 | 137.6× | 0.002 | IL6, IL6R |
| T cell differentiation | 3 | 32.8× | 0.003 | IL2, PTPN2, PTPN22 |
| negative regulation of T cell receptor signaling pathway | 3 | 31.4× | 0.003 | CD80, PTPN2, PTPN22 |
| interleukin-12-mediated signaling pathway | 2 | 107.0× | 0.003 | STAT4, TYK2 |
| activated T cell proliferation | 2 | 107.0× | 0.003 | IL2, IL2RA |
| germinal center B cell differentiation | 2 | 96.3× | 0.004 | IL21, IL6 |
| negative regulation of lipid storage | 2 | 87.5× | 0.004 | IL6, PTPN2 |
| peripheral nervous system neuron development | 2 | 87.5× | 0.004 | RUNX1, RUNX3 |
| T-helper 17 cell lineage commitment | 2 | 87.5× | 0.004 | IL6, IL6R |
| cell surface receptor signaling pathway via JAK-STAT | 3 | 24.9× | 0.004 | STAT4, TYK2, IL6 |
| neutrophil mediated immunity | 2 | 80.2× | 0.004 | IL6, IL6R |
| T follicular helper cell differentiation | 2 | 80.2× | 0.004 | IL21, IL6 |
| positive regulation of leukocyte chemotaxis | 2 | 74.1× | 0.005 | IL6, IL6R |
| type II interferon-mediated signaling pathway | 2 | 68.8× | 0.005 | TYK2, IRF1 |
| positive regulation of neuroinflammatory response | 2 | 68.8× | 0.005 | CCR1, IL6 |
Therapeutics
Drug target analysis
Approved (phase 4): 5 · Phase ≥3: 5 · Phased (≥1): 9 · Undrugged: 28
Druggability breadth: 22 of 37 evidence-associated genes (59%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Genes with an approved drug
The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.
| Symbol | Example approved molecule |
|---|---|
| RUNX1 | APOMORPHINE HYDROCHLORIDE |
| TYK2 | FEDRATINIB |
| CCR1 | ABAMETAPIR |
| FASN | RABEPRAZOLE |
| IL6 | PREDNISOLONE |
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| TYK2 | 72 | 4 |
| CCR1 | 8 | 4 |
| FASN | 8 | 4 |
| PTPN2 | 4 | 2 |
| IL6 | 3 | 4 |
| RUNX1 | 2 | 4 |
| CCR3 | 2 | 2 |
| IL2 | 2 | 2 |
| ERAP2 | 1 | 2 |
| RUNX3 | 0 | 0 |
Drugs targeting cohort genes (top 30)
| Molecule | Max phase | Targets in cohort |
|---|---|---|
| APOMORPHINE HYDROCHLORIDE | 4 | RUNX1 |
| FEDRATINIB | 4 | TYK2 |
| RUXOLITINIB | 4 | TYK2 |
| TOFACITINIB | 4 | TYK2 |
| UPADACITINIB | 4 | TYK2 |
| BARICITINIB | 4 | TYK2 |
| FILGOTINIB | 4 | TYK2 |
| ABROCITINIB | 4 | TYK2 |
| DEUCRAVACITINIB | 4 | TYK2 |
| MOMELOTINIB | 4 | TYK2 |
| AXITINIB | 4 | TYK2 |
| RUXOLITINIB PHOSPHATE | 4 | TYK2 |
| INFIGRATINIB PHOSPHATE | 4 | TYK2 |
| INFIGRATINIB | 4 | TYK2 |
| PACRITINIB | 4 | TYK2 |
| TOFACITINIB CITRATE | 4 | TYK2 |
| BOSUTINIB | 4 | TYK2 |
| PEFICITINIB | 4 | TYK2 |
| CRAVACITINIB | 4 | TYK2 |
| PAZOPANIB | 4 | TYK2 |
| NINTEDANIB | 4 | TYK2 |
| SUNITINIB | 4 | TYK2 |
| DASATINIB | 4 | TYK2 |
| ERLOTINIB | 4 | TYK2 |
| CRIZOTINIB | 4 | TYK2 |
| MIDOSTAURIN | 4 | TYK2 |
| IMATINIB | 4 | TYK2 |
| ABAMETAPIR | 4 | CCR1 |
| RALTEGRAVIR | 4 | CCR1 |
| RABEPRAZOLE | 4 | FASN |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 8.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| TYK2 | 1,083 | Binding:1043, Functional:39, ADMET:1 |
| PTPN2 | 250 | Binding:246, ADMET:4 |
| CCR1 | 243 | Binding:176, Functional:67 |
| CCR3 | 175 | Binding:107, Functional:68 |
| FASN | 142 | Binding:136, Functional:6 |
| PTPN22 | 137 | Binding:122, Functional:10, ADMET:5 |
| ERAP2 | 46 | Binding:40, ADMET:4, Functional:2 |
| IL2 | 35 | Binding:34, ADMET:1 |
| LNPEP | 34 | Binding:33, ADMET:1 |
| RUNX1 | 20 | Binding:17, Functional:3 |
| STAT4 | 20 | Binding:20 |
| IL6 | 16 | Binding:16 |
| ATXN2 | 5 | Binding:3, Functional:2 |
| IL6R | 5 | Binding:5 |
| UBE2L3 | 2 | Binding:2 |
| COG6 | 2 | Binding:2 |
| IL2RA | 2 | Binding:2 |
| LONRF2 | 1 | Binding:1 |
| IL2RB | 1 | Binding:1 |
| LTBR | 1 | Binding:1 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|---|---|
| TYK2 | 2.7.10.2 | non-specific protein-tyrosine kinase |
| UBE2L3 | 2.3.2.23, 2.3.2.24 | E2 ubiquitin-conjugating enzyme, (E3-independent) E2 ubiquitin-conjugating enzyme |
| ATP8B2 | 7.6.2.1 | P-type phospholipid transporter |
| ERAP2 | 3.4.11.1, 3.4.11.6 | leucyl aminopeptidase, aminopeptidase B |
| FASN | 2.3.1.39, 2.3.1.85 | [acyl-carrier-protein] S-malonyltransferase, fatty-acid synthase system |
| LNPEP | 3.4.11.3 | cystinyl aminopeptidase |
| PTPN2 | 3.1.3.48 | protein-tyrosine-phosphatase |
| PTPN22 | 3.1.3.48 | protein-tyrosine-phosphatase |
Cohort genes with high screening signal
≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.
| Symbol | ChEMBL assays |
|---|---|
| TYK2 | 1,083 |
| CCR1 | 243 |
| CCR3 | 175 |
| FASN | 142 |
| PTPN2 | 250 |
| PTPN22 | 137 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 37; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
| Compound | Max phase | Cohort target (bioactivity) |
|---|---|---|
| APOMORPHINE HYDROCHLORIDE | 4 | RUNX1 |
| FEDRATINIB | 4 | TYK2 |
| RUXOLITINIB | 4 | TYK2 |
| TOFACITINIB | 4 | TYK2 |
| UPADACITINIB | 4 | TYK2 |
| BARICITINIB | 4 | TYK2 |
| FILGOTINIB | 4 | TYK2 |
| ABROCITINIB | 4 | TYK2 |
| DEUCRAVACITINIB | 4 | TYK2 |
| MOMELOTINIB | 4 | TYK2 |
| AXITINIB | 4 | TYK2 |
| RUXOLITINIB PHOSPHATE | 4 | TYK2 |
| INFIGRATINIB PHOSPHATE | 4 | TYK2 |
| INFIGRATINIB | 4 | TYK2 |
| PACRITINIB | 4 | TYK2 |
| TOFACITINIB CITRATE | 4 | TYK2 |
| BOSUTINIB | 4 | TYK2 |
| PEFICITINIB | 4 | TYK2 |
| CRAVACITINIB | 4 | TYK2 |
| PAZOPANIB | 4 | TYK2 |
| NINTEDANIB | 4 | TYK2 |
| SUNITINIB | 4 | TYK2 |
| DASATINIB | 4 | TYK2 |
| ERLOTINIB | 4 | TYK2 |
| CRIZOTINIB | 4 | TYK2 |
| MIDOSTAURIN | 4 | TYK2 |
| IMATINIB | 4 | TYK2 |
| ABAMETAPIR | 4 | CCR1 |
| RALTEGRAVIR | 4 | CCR1 |
| RABEPRAZOLE | 4 | FASN |
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 5 | RUNX1, TYK2, CCR1, FASN, IL6 |
| B | Phased (≥1) drug, not yet approved | 4 | CCR3, ERAP2, IL2, PTPN2 |
| C | Druggable family + PDB, no drug | 8 | UBE2L3, CD80, HLA-DQB1, IL2RA, IL2RB, IL6R, LNPEP, PTPN22 |
| D | Druggable family + AlphaFold only, no drug | 1 | HLA-DQA2 |
| E | Difficult family or no structure, no drug | 19 | RUNX3, ATXN2, ZFP36L1, STAT4, TIMMDC1, ATP8B2, COG6, LONRF2, ANKRD55, PRR5L (+9 more) |
Undrugged target profiles
28 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| STAT4 | 20 | TYK2 |
| IL6R | 5 | IL6 |
| PTPN22 | 137 | — |
| RUNX3 | 0 | — |
| ATXN2 | 5 | — |
| ZFP36L1 | 0 | — |
| UBE2L3 | 2 | — |
| TIMMDC1 | 0 | — |
| ATP8B2 | 0 | — |
| CD80 | 0 | — |
| COG6 | 2 | — |
| LONRF2 | 1 | — |
| ANKRD55 | 0 | — |
| PRR5L | 0 | — |
| RMI2 | 0 | — |
| JAZF1 | 0 | — |
| SH2B3 | 0 | — |
| CARINH | 0 | — |
| HLA-DQA2 | 0 | — |
| HLA-DQB1 | 0 | — |
| IL21 | 0 | — |
| IL2RA | 2 | — |
| IL2RB | 1 | — |
| IRF1 | 0 | — |
| AFF3 | 0 | — |
| LNPEP | 34 | — |
| LTBR | 1 | — |
| PRM1 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.